The latest Investing Matters Podcast episode with London Stock Exchange Group's Chris Mayo has just been released. Listen here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksYGEN.L Regulatory News (YGEN)

  • There is currently no data for YGEN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Business update

30 Apr 2007 07:49

ViaLogy PLC30 April 2007 Date: 30 April 2007On behalf of: ViaLogy plc ("ViaLogy" or "the Company") For immediate release ViaLogy PLC Business Update Vialogy SPMTM selected by US Department of Defence for joint experiments todevelop Joint Forces Protection and Base Security Systems London, April 30, 2007 -- ViaLogy PLC (LSE: VIY), announces that its Americansubsidiary, ViaLogy LLC, has been chosen by the US Department of Defence (DoD)to participate in joint experiments to support next-generation Joint ForceProtection Advanced Security (JFPASS) Joint Capabilities TechnologyDemonstration (JCTD). ViaLogy was selected to provide a Command and Controlplatform for the experiments. Recent DoD studies have found that current technologies, as employed, do notprovide a comprehensive, integrated and sustainable Joint Force Protectioncapability. The goal of JFPASS is to address these shortcomings with a potential$60 million combined services project to begin in 2008. The JFPASS JCTD is a joint services (Army, Navy, Air Force and Marines)initiative for integrating tactical systems, sensors and security personnel toprotect forces and over 600 facilities in the US and overseas. NATO and othercoalition partners have similar needs for base and force protection globally. ViaLogy will be providing its SPMTM (Sensor Policy Manager) product for theinternet protocol-enabled sensors and systems to accurately and immediatelyinterpret and disseminate information to pre-selected destinations. The lack ofsuch an effective interoperability between systems has previously been asignificant problem for both the military and public sectors. At a recent integration assessment supporting JFPASS JCTD in the Space and NavalWarfare Systems Centre (SPAWAR), San Diego, CA, ViaLogy successfullydemonstrated interoperability between two disparate operators, NorthropGrumman's Tactical Asset Security System (TASS) and the Joint BattlespaceCommand and Control Station (JBC2S) for unmanned systems. ViaLogy has alsointegrated a Lightweight Chemical Detector (LCD) from Smiths Detection tovalidate the IP-based plug-and-play capabilities of SPMTM. The LCD is part ofthe soldiers' hand-held equipment and is used for checking cargo, personnel orbuildings for chemical warfare agents. ViaLogy's SPMTM product provides a sensor-based policy engine for the rapiddetection, analysis and transmission of information. It exploits internetprotocol and patented signal processing to deliver interoperability to sensor,video and network sub-systems. Of major importance to potential users of SPMTM are its reliability,adaptability and affordability. "The product is designed for scaleableimplementation involving hundreds and even thousands of sensors," said Dr.Sandeep Gulati, ViaLogy's Chief Technology Officer. "JFPASS requirements presentan ideal opportunity for SPMTM. The technology thrives on the unexpected and, inthe event of a major incident, plays a vital role in detection and effectivedamage control." Previously, as NASA's Jet Propulsion Laboratory PrincipalScientist for sensor fusion, Dr. Gulati was extensively involved with sensorintensive command and control systems. ViaLogy CEO, Mr. Shah Talukder stated: "Higher demand for commercialoff-the-shelf products will shift procurement from project-centric toproduct-centric acquisition of technology. This will drive down project costsand timelines as it does in private sector procurement." Mr. Talukder who, prior to joining ViaLogy, developed the vision, strategy androad map for Cisco's Interoperability and Collaboration System (IPICS), added: "By delivering comprehensive sensor, video and tactical interoperability in anetwork-centric platform we believe SPM product will be able to meet JFPASS JCTDrequirements and play an integral part in the joint forces security project." For further information please contact: ViaLogy Shah Talukder, CEO - US +1 626-296-6337Terry Bond, Chairman - UK & Europe +44 (0)20 2869 7014 Redleaf CommunicationsEmma Kane / Samantha Robbins +44 (0)20 7822 0200 Seymour Pierce Limited (NOMAD)Mark Percy +44 (0)20 7107 8000 About ViaLogy: Network Centric Signal Processing. ViaLogy is a leading innovator of network-centric, real-time signal processingplatforms for sensor applications. ViaLogy is currently deploying and designingcomputational systems, powered by its patented technologies, for applications inlife sciences, public safety and security, surveillance, defense andgeoseismology. Vialogy focuses on market driven problems where automation,timeliness, quality and reliability of information processing are essential.ViaLogy's core competency incorporates rapidly and accurately detecting weaksignals buried in high noise background and clutter. This technology can beemployed to solve problems involving sensor integration and information overloadchallenges involving video, telephony and control sensors, as well as forenhancement of numerous signal processing applications. For more information,visit our website at www.vialogy.com. Except for statements of historical fact, the information presented hereinconstitutes forward-looking statements within the meaning of the PrivateSecurities Litigation Reform Act of 1995. Such forward-looking statementsinvolve known and unknown risks, uncertainties and other factors which may causethe actual results, performance or achievements of the company to be materiallydifferent from any future results, performance or achievements expressed orimplied. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
14th Dec 20217:00 amRNSHalf-year Report
6th Dec 20217:00 amRNSNotice of Half-year results
18th Nov 20217:00 amRNSDPYD screening recommended in Spain
28th Oct 20217:00 amRNSRanger® Technology to be presented at Labroots
26th Oct 20217:00 amRNSHalf-year Trading update
29th Sep 20217:00 amRNSResult of AGM
28th Sep 20213:00 pmRNSAGM update
28th Sep 20217:00 amRNSAGM Statement
15th Sep 20217:00 amRNSShare option awards
1st Sep 20217:00 amRNSISO 15189:2012 accreditation received
1st Sep 20217:00 amRNSNotice of AGM and Annual Report 2021
19th Aug 202112:04 pmRNSCOVID-19 Surge testing contract
11th Aug 20217:01 amRNSEarn-out Milestone, Issue of Equity & TVR
11th Aug 20217:00 amRNSAudited Final results&unaudited Q1 business update
6th Aug 20217:00 amRNSConfirmation of Results Date
23rd Jul 20217:00 amRNSNotice of Results
1st Jul 202111:09 amRNSHolding(s) in Company
21st Jun 20217:00 amRNSSecond Strategic Partner for Coastal Genomics
18th Jun 20217:00 amRNSContract Award: DPYD testing kits for NHS Wales
17th Jun 20214:32 pmRNSExercise of Options
9th Jun 20217:00 amRNSMulti-year licence and supply agreement
21st May 20214:30 pmRNSDirector/PDMR Shareholding
19th May 20217:00 amRNSDistribution Partnership
18th May 20217:00 amRNSLaunch of IONA Care NIPT service offering
17th May 20217:00 amRNSFurther testing service agreement for MHC
29th Apr 20217:00 amRNSFull year Trading update
26th Apr 20217:00 amRNSFurther National Microbiology Framework awards
19th Apr 20211:21 pmRNSFurther National Microbiology Framework contract
19th Apr 20217:00 amRNSNational Framework contract award
12th Apr 20217:00 amRNSEarn-out Milestone, Issue of Equity & TVR
6th Apr 20212:43 pmRNSTesting service agreement with MyHealthCheckedplc
6th Apr 20211:54 pmRNSAgreement with Boots for COVID-19 sample kits
29th Mar 20214:00 pmRNSCOVID-19 update
23rd Mar 20217:00 amRNSShare option exercises and awards
19th Mar 20217:00 amRNSTwin Pregnancy study published using IONA® Test
17th Mar 20217:00 amRNSAppointment of VP of Sales North America
11th Mar 20217:00 amRNSYourgene Genomic Services portfolio expansion
1st Mar 20217:00 amRNSFirst US Supply Agreement
22nd Feb 20217:00 amRNSPartnership with NPH
10th Feb 202110:51 amRNSCorrection: Director / PDMR Shareholding
10th Feb 20217:00 amRNSDirector/PDMR Shareholding
8th Feb 20217:00 amRNSTrading update
13th Jan 20217:00 amRNSDPYD screening recommended in Belgium
11th Jan 20217:00 amRNSClarigene® SARS-CoV-2 Product Update
8th Jan 20217:00 amRNSIssue of Share Options
24th Dec 20207:00 amRNSCOVID-19 update
17th Dec 20207:00 amRNSHalf-year Report
15th Dec 20207:00 amRNSNotice of Half-year Results
2nd Dec 20207:00 amRNSDPYD kits recommended by NHS England
2nd Dec 20207:00 amRNSGenomic testing service launch and Change of name

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.